Michael J. Grant MD
Assistant Professor of Medicine, Yale Cancer Center, New Haven, ConnecticutMichael Grant, MD, is an Assistant Professor of Medicine (Medical Oncology). Dr. Grant received his medical degree from the Albert Einstein School of Medicine and did his residency in Internal Medicine at Duke University School of Medicine. He completed his fellowship at Yale School of Medicine during which he was enrolled in the Yale Cancer Center T32 Advanced Training Program (YCC-ATPP) for Physician-Scientists. The YCC-ATPP provides funding to fellows who are strongly committed to being independent physician-scientists performing basic, translational, clinical, or outcomes research in a cancer-related field.
Dr. Grant cares for patients with thoracic and genitourinary malignancies and his current research interests include targeted and immunotherapy approaches to the treatment of non-small cell lung cancer. In 2021, he received the ASCO Conquer Cancer Young Investigator Award to study sensitivity and resistance to EGFR-targeted therapies in patients with NSCLC harboring certain EGFR mutations.
Recent Contributions to PracticeUpdate:
- Isolated CNS Recurrence After Definitive Therapy for Stage III NSCLC
- First-Line Therapy for Metastatic Squamous Lung Cancer With PD-L1 0%
- ALK-Rearranged Oligometastatic NSCLC
- A 76-Year-Old Man With COPD and Metastatic Lung Adenocarcinoma
- Advanced NSCLC: Anti-PD-1 Rechallenge After Immune-Related Toxicity
- Stage IIIB Lung Adenocarcinoma With EGFR L858R Mutation
- Meeting Unmet Needs in Precision Therapy for NSCLC: Promising Therapies From WCLC 2020—Introduction
- Meeting Unmet Needs in Precision Therapy for NSCLC: Promising Therapies From WCLC 2020—Sotorasib
- Meeting Unmet Needs in Precision Therapy for NSCLC: Promising Therapies From WCLC 2020—Amivantamab
- Optimal First-Line Precision Therapy for Adenocarcinoma